In the case of a vaccine capable of protecting against leishmaniasis, it is desirable that it induces a Th1-type immune response profile, where the pro-inflammatory cytokine IFN-γ/TNF must overcome the effects of the regulatory cytokine IL-10, while susceptibility is related to a deficient Th1 response [27]. The gene discussed is IL10; the disease is leishmaniasis.